In a preclinical NSCLC study, it was shown that mocetinostat, a class I/IV HDACi, together with anti-PD-L1 antibody augmented the antitumor activity by decreasing the immune suppressive cell types and increasing CD8+ T cell infiltration in the TME [57]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.